Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Neurobiol Dis. 2020 Apr 14;141:104871. doi: 10.1016/j.nbd.2020.104871

Table 2.

Questions to consider regarding clinical use of genetic susceptibility testing for neurodegenerative disease

Patient Factors
  • Does the patient have a family history of the condition?

  • Does the patient have children, siblings or other at-risk relatives?

  • Is the patient already experiencing possible symptoms?

  • Is the patient cognitively able to comprehend the information to make an informed decision and understand the results?

  • Is the patient psychologically able to cope with test results?

  • Does the patient have identified sources of support (e.g., family members, friends) and access to supportive resources?

  • Does the patient have desired insurance coverage – health, life, long-term disability, long-term care?

Disease Characteristics
  • How common is the neurodegenerative disease in question?

  • Is the condition typically sporadic or inherited?

  • What is the typical inheritance pattern of the disease?

  • What is the typical disease course and does this vary by gene mutation?

  • Is the patient approaching or beyond the typical age of onset of symptoms?

  • Are there options for prevention and surveillance?

Genetic Testing and Counseling
  • Who is the most appropriate clinician to order the genetic testing?

  • What is the positive predictive value of the genetic test?
    • What is the significance of having a gene mutation identified – e.g., is there reduced penetrance, variable expressivity, genotype-phenotype correlations?
  • Will genetic test results impact a patient’s care and management?

  • Will genetic test results impact a patient’s life decisions?

  • Why is the patient seeking genetic testing at this time?

  • Does the patient plan to share results with their health care providers (if ordering DTC) and with other family members?

  • Has the patient been informed about and provided with supportive resources?

Reproduced from Roberts & Uhlmann, 2013

HHS Vulnerability Disclosure